West Cash from 2010 to 2025

WST Stock  USD 227.51  0.00  0.00%   
West Pharmaceutical Cash yearly trend continues to be comparatively stable with very little volatility. Cash is likely to outpace its year average in 2025. Cash is the total amount of money in the form of currency that West Pharmaceutical Services has in its possession. This includes all bills, coins, and funds in bank accounts. View All Fundamentals
 
Cash  
First Reported
1985-12-31
Previous Quarter
490.9 M
Current Value
484.6 M
Quarterly Volatility
220 M
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check West Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among West Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 163.2 M, Total Revenue of 3 B or Gross Profit of 1 B, as well as many indicators such as Price To Sales Ratio of 8.68, Dividend Yield of 0.0023 or PTB Ratio of 9.36. West financial statements analysis is a perfect complement when working with West Pharmaceutical Valuation or Volatility modules.
  
Check out the analysis of West Pharmaceutical Correlation against competitors.

Latest West Pharmaceutical's Cash Growth Pattern

Below is the plot of the Cash of West Pharmaceutical Services over the last few years. Cash refers to the most liquid asset of West Pharmaceutical, which is listed under current asset account on West Pharmaceutical Services balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from West Pharmaceutical customers. The amounts must be unrestricted with restricted cash listed in a different West Pharmaceutical account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. West Pharmaceutical's Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in West Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
Cash10 Years Trend
Slightly volatile
   Cash   
       Timeline  

West Cash Regression Statistics

Arithmetic Mean397,326,875
Geometric Mean278,063,004
Coefficient Of Variation67.81
Mean Deviation222,192,734
Median337,400,000
Standard Deviation269,426,952
Sample Variance72590.9T
Range885.8M
R-Value0.84
Mean Square Error23091.7T
R-Squared0.70
Significance0.00005
Slope47,452,132
Total Sum of Squares1088863.2T

West Cash History

2025508.8 M
2024484.6 M
2023853.9 M
2022894.3 M
2021762.6 M
2020615.5 M
2019439.1 M

Other Fundumenentals of West Pharmaceutical

West Pharmaceutical Cash component correlations

About West Pharmaceutical Financial Statements

West Pharmaceutical shareholders use historical fundamental indicators, such as Cash, to determine how well the company is positioned to perform in the future. Although West Pharmaceutical investors may analyze each financial statement separately, they are all interrelated. The changes in West Pharmaceutical's assets and liabilities, for example, are also reflected in the revenues and expenses on on West Pharmaceutical's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Cash484.6 M508.8 M
Cash And Short Term Investments484.6 M508.8 M
Cash And EquivalentsB548.1 M
Change In Cash-369.3 M-350.8 M
Free Cash Flow276.4 M290.2 M
Begin Period Cash Flow853.9 M896.6 M
Other Cashflows From Financing Activities30.7 M51.3 M
Other Non Cash Items-16.3 M-15.5 M
Total Cash From Operating Activities653.4 M686.1 M
Total Cash From Financing Activities-622.6 M-591.5 M
End Period Cash Flow484.6 M508.8 M
Other Cashflows From Investing Activities-1.7 M-1.6 M
Total Cashflows From Investing Activities-259.4 M-246.4 M
Cash And Cash Equivalents Changes163.5 M171.7 M
Cash Flows Other Operating87.4 M91.8 M
Free Cash Flow Yield 0.01  0.01 
Operating Cash Flow Per Share 8.95  9.40 
Free Cash Flow Per Share 3.79  3.98 
Cash Per Share 6.64  6.97 
Capex To Operating Cash Flow 0.58  0.77 
EV To Operating Cash Flow 36.32  38.13 
EV To Free Cash Flow 85.85  90.14 
Price To Operating Cash Flows Ratio 36.60  38.43 
Price To Free Cash Flows Ratio 86.51  90.84 
Cash Ratio 0.88  0.47 
Cash Conversion Cycle 96.23  95.18 
Operating Cash Flow Sales Ratio 0.23  0.12 
Free Cash Flow Operating Cash Flow Ratio 0.42  0.24 
Cash Flow Coverage Ratios 2.16  2.27 
Price Cash Flow Ratio 36.60  38.43 
Cash Flow To Debt Ratio 2.16  2.27 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for West Stock Analysis

When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.